Q32-35: Concomitant Therapy

Question 32: Did the recipient receive concomitant therapy?

Concomitant therapy is any therapy given to increase the effectiveness of the cellular therapy or decrease the toxicity. In cases where a recipient has both HCT and cell therapy, this question applies to the cell therapy infusion, not the HCT. If the recipient had a prior HCT and the therapy was already captured on the HCT form as being HCT prep regimen, it is not reported again. See question 34 for a list of drugs that can be given as concomitant therapy.

*Questions 33-35 Reporting More Than One Concomitant Therapy
FormsNet3^SM application: Complete questions 33-35 for each concomitant therapy by adding an additional instance in the FormsNet^SM application.
Paper form submission: Copy questions 33-35 and complete for each concomitant therapy.

Question 33: Specify start date:

Report the start date of the drug selected in question 34. Concomitant therapy can be given simultaneously with the cellular therapy infusion or post cell therapy.

Question 34-35: Specify drugs:

Select the drug(s) given as concomitant therapy. If the drug given is not in the list, check Other and specify the drug in question 35.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
32	12/12/23	Modify	Updated the definition of concomitant therapy: Concomitant therapy is any therapy given to increase the effectiveness of the cellular therapy or decrease the toxicity enhance the function of the cellular therapy	Updated the definition of concomitant therapy and removed the post-infusion time point reference.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.